search
Back to results

Treatment for First-Episode Schizophrenia

Primary Purpose

Schizophrenia

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Olanzapine
Risperidone
Sponsored by
Northwell Health
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring Adolescence, Adult, Antipsychotic Agents, Female, Human, Male, olanzapine, Risperidone, Schizophrenia, Antipsychotic Agents -- *therapeutic use, olanzapine -- *therapeutic use, Risperidone -- *therapeutic use, Schizophrenia -- *drug therapy

Eligibility Criteria

16 Years - 40 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: First episode schizophrenia, schizophreniform disorder or schizoaffective disorder Exclusion Criteria: Prior treatment with antipsychotic medications.

Sites / Locations

  • Bronx-Lebanon Hospital Center
  • Hillside Hospital

Outcomes

Primary Outcome Measures

Treatment response

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
January 12, 2012
Sponsor
Northwell Health
Collaborators
National Institute of Mental Health (NIMH), The Zucker Hillside Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00000374
Brief Title
Treatment for First-Episode Schizophrenia
Official Title
Preventing Morbidity in First-Episode Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
September 1998 (undefined)
Primary Completion Date
May 2007 (Actual)
Study Completion Date
May 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwell Health
Collaborators
National Institute of Mental Health (NIMH), The Zucker Hillside Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
Detailed Description
The goal of the study is to prevent morbidity in first-episode schizophrenia using second-generation antipsychotic drugs: olanzapine, risperidone. Long-term studies of first-episode schizophrenia patients have clearly indicated excellent initial responsiveness of positive psychotic symptoms to treatment with conventional antipsychotic medications. However, in the years immediately following this initial good response, morbidity increases. Relapses, often multiple ones, are the rule and are usually precipitated by medication noncompliance. There is some evidence that the second-generation antipsychotic drugs may have superior efficacy in terms of these outcome domains. However, these newer agents have been studied primarily in chronic and/or treatment-resistant patient samples and there are virtually no long-term studies or studies comparing the new drugs with one another. First episode patients are randomly assigned to treatment with olanzapine or risperidone for 3 years. Outcome measures for the initial episode include psychopathology (positive, negative, and affective symptoms), side effects, neurocognition (executive function, memory, and attention), social and occupational function and service utilization. The effects on long-term course are measured in terms of frequency and timing of relapses, level of recovery from subsequent episodes and prospectively assessed course of psychopathology, neurocognitive function, social/vocational function, and service utilization. For information on a related study, please follow this link: http://clinicaltrials.gov/show/NCT00320671

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
Adolescence, Adult, Antipsychotic Agents, Female, Human, Male, olanzapine, Risperidone, Schizophrenia, Antipsychotic Agents -- *therapeutic use, olanzapine -- *therapeutic use, Risperidone -- *therapeutic use, Schizophrenia -- *drug therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
125 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Olanzapine
Intervention Description
The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
Intervention Type
Drug
Intervention Name(s)
Risperidone
Intervention Description
The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
Primary Outcome Measure Information:
Title
Treatment response
Time Frame
8 consecutive weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: First episode schizophrenia, schizophreniform disorder or schizoaffective disorder Exclusion Criteria: Prior treatment with antipsychotic medications.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Delbert Robinson, MD
Organizational Affiliation
The Zucker Hillside Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bronx-Lebanon Hospital Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10456
Country
United States
Facility Name
Hillside Hospital
City
Glen Oaks
State/Province
New York
ZIP/Postal Code
11004
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21939612
Citation
Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry. 2011 Dec;72(12):1691-6. doi: 10.4088/JCP.10m06349. Epub 2011 Sep 6.
Results Reference
derived

Learn more about this trial

Treatment for First-Episode Schizophrenia

We'll reach out to this number within 24 hrs